No Data
Laekna Doses All Subjects in LAE102 Phase I Trial
Coming Kai Medicine-B (02105.HK): All subjects have completed dosing in the Phase I single ascending dose study (SAD study) of LAE102 for the treatment of obesity.
On December 4, Gelonghui reported that Comei Pharmaceuticals-B (02105.HK) announced that the Phase I clinical trial of LAE102 is progressing smoothly. As of the date of this announcement, all participants in this Phase I single ascending dose study ("SAD study") have completed administration, including 8 intravenous infusion and subcutaneous injection dose escalation cohorts, totaling 64 participants. Early signs of target binding and expected changes in pharmacodynamic biomarkers have been observed, along with good safety. This Phase I clinical trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the injection of LAE102 in healthy adult participants.
Global pharmaceutical leader eli lilly and co and Luye Pharma (02105) cooperate to start a new upswing in the pharmaceutical industry.
Competition in the global market of weight-loss drugs targeting GLP-1 has heated up. Domestic Biotech company LK Healthcare (02105) is expected to be the first to share this large global market for fat loss and muscle gains.
Laekna Obesity Drug Begins Clinical Study
Laekna Starts Investigational New Drug-Enabling Study for Muscle Weakness Pill
Lai Kai Pharmaceuticals-B (02105.HK) completed the issuance with a total of 17.636 million shares.
On November 27, Glonghui reported that Kai Medical-B (02105.HK) announced that the board of directors is pleased to declare that all conditions for the placement have been met, and the placement was completed on November 27, 2024. According to the terms and conditions of the placement agreement, 17,636,000 shares were successfully placed by the exclusive placing agent at a placement price of 13.36 Hong Kong dollars per share to no fewer than six assignees.
No Data
